


PTO-1449	ATTY. DOCKET NO. MERZ 32 PCT US	SERIAL NO. 10/018,373
LIST OF PRIOR ART CITED BY APPLICANT	APPLICANT Hans BIGALKE and Jürgen FREVERT	
SHEET <u>1</u> OF <u>12</u>	FILING DATE December 6, 2001	GROUP 1645



#### U.S. PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO

#### OTHER PRIOR ART

	Hatheway CL and Dang C, Immunogenicity of the immunotoxins of <i>Clostridium botulinum</i> . In: Jankovic J and Hallett M, eds. <i>Therapy with botulinum toxin</i> . New York: Marcel Dekker, 1994, pp.93-97.
	Greene P, Fahn S and Diamond B. 1994. Development of Resistance to Botulinum Toxin Type A in Patients with Torticollis. <i>Movement Disorders</i> 9:213-217.
	Jankovic J and Schwartz K. 1995. Response and immunoresistance to botulinum toxin injections. <i>Neurobiology</i> 45:1743-1746.
	Borodic, Johnson E Goodnough M and Schantz E. 1996. Botulinum toxin therapy, immunologic resistance, and problems with available materials. <i>Neurology</i> 46:26-29.
	Dertzbaugh MT and West MW. 1996. Mapping of protective and cross-reactive domains of the type A neurotoxin of <i>Clostridium botulinum</i> . <i>Vaccine</i> 14:1538-1544.
	Doellgast GJ, Brown JE, Koufman JA and Hatheway C. 1997. Sensitive Assay for Measurement of Antibodies to <i>Clostridium botulinum</i> Neurotoxins A, B, and E: Use of Hapten-Labeled Antibody Elution To Isolate Specific Complexes. <i>J. Clinical Microbiol.</i> 35:578-583.
	Dressler D. 1997. Botulinum toxin therapy failure: causes, evaluation procedures and management strategies. <i>European J. Neurology</i> 4 (suppl 2):S67-S70.
	Brin MF. 1997. Botulinum Toxin: Chemistry, Pharmacology, Toxicity, and Immunology. <i>Muscle &amp; Nerve Supplement</i> 6:S146-S168.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO-1449  LIST OF PRIOR ART CITED BY APPLICANT  SHEET <u>2</u> OF <u>2</u>	ATTY. DOCKET NO. MERZ 32 PCT US	SERIAL NO. 10/018,373
	APPLICANT Hans BIGALKE and Jürgen FREVERT	
	FILING DATE December 6, 2001	GROUP 1645

OTHER PRIOR ART

	Kessler KR, Skutta M and Benecke R. 1999. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J. Neurol. 246:265-274.
	Aoki, KR. 1999. Preclinical update on BOTOX® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. European Journal of Neurology 6 (suppl. 4):S3-S10.
	Brashear A. 2001. The Botulinum Toxins in the Treatment of Cervical Dystonia. Seminars in Neurology 21:85-90.
	Aoki KR and Guyer B. 2001 Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. European Journal of Neurology 8 (suppl. 5):21-29.
	Jankovic J. Botulinum Toxin: Clinical Implications of Antigenicity and Immunoresistance. In: Brin MF, Jankovic J and Hallett M eds. <i>Scientific and Therapeutic Aspects of Botulinum Toxin</i> . Philadelphia: Lippincott Williams & Wilkins, 2002, pp.409-415.
	Aoki KR. Immunologic and Other Properties of Therapeutic Botulinum Toxin Serotypes. . In: Brin MF, Jankovic J and Hallett M eds. <i>Scientific and Therapeutic Aspects of Botulinum Toxin</i> . Philadelphia: Lippincott Williams & Wilkins, 2002, pp.103-113.
	Aoki KR. Physiology and Pharmacology of Therapeutic Botulinum Neurotoxins. In: Kreyden OP, Böni R and Burg G eds. <i>Hyperhidrosis and Botulinum Toxin in Dermatology</i> . Curr Probl Dermatol, Basel: Karger, 2002, vol. 30, pp. 107-116.
	Aoki KR 2002. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon 40:923-928.
	Eleopra R, Tungnoli V Quatrala R Rossetto O, Montecucco C and De Grandis D. Botulinum Neurotoxin Serotypes C and E: Clinical Trials. In: Brin MF, Jankovic J and Hallett M eds. <i>Scientific and Therapeutic Aspects of Botulinum Toxin</i> . Philadelphia: Lippincott Williams & Wilkins 2002, pp. 441-450.
	Münchau A, Palmer JK, Dressler K, O'Sullivan JD Tsang KL, Jahanshahi M, Quinn NP, Lees AJ, Bhatia KP. 2001. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. Brain 124:769-83.

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	